Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study ; volume:12 ; number:5 ; day:27 ; month:6 ; year:2023 ; pages:2781-2792 ; date:10.2023
Ophthalmology and therapy ; 12, Heft 5 (27.6.2023), 2781-2792, 10.2023
- Urheber
-
Rousseau, Nicolas
Lebreton, Olivier
Masse, Hélène
Maucourant, Yann
Pipelart, Valentin
Clement, Manon
Le Lez, Marie-Laure
Khanna, Raoul Kanav
Pepin, Maxime
Eude, Yannick
Le Meur, Guylène
Weber, Michel
Ducloyer, Jean-Baptiste
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40123-023-00749-2
- URN
-
urn:nbn:de:101:1-2023110607575263007155
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rousseau, Nicolas
- Lebreton, Olivier
- Masse, Hélène
- Maucourant, Yann
- Pipelart, Valentin
- Clement, Manon
- Le Lez, Marie-Laure
- Khanna, Raoul Kanav
- Pepin, Maxime
- Eude, Yannick
- Le Meur, Guylène
- Weber, Michel
- Ducloyer, Jean-Baptiste
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Dexamethasone Implant Migration through an Iris Coloboma
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema
Dexamethasone implant confined in Berger’s space
Dexamethasone Implant as Sole Therapy in Sympathetic Ophthalmia
Dexamethasone implant in silicone oil: in vitro behavior
Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients : Corneal endothelium after dexamethasone implant injection
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Dexamethasone Implant Migration through an Iris Coloboma
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema
Dexamethasone implant confined in Berger’s space
Dexamethasone Implant as Sole Therapy in Sympathetic Ophthalmia
Dexamethasone implant in silicone oil: in vitro behavior
Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients : Corneal endothelium after dexamethasone implant injection
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Dexamethasone Implant Migration through an Iris Coloboma
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema
Dexamethasone implant confined in Berger’s space
Dexamethasone Implant as Sole Therapy in Sympathetic Ophthalmia
Dexamethasone implant in silicone oil: in vitro behavior